Stock Track | Bicara Therapeutics Soars 5% as Multiple Analysts Boost Price Targets

Stock Track

Nov 11, 2025

Shares of Bicara Therapeutics (BCAX) are soaring 5.03% in Tuesday's trading session, fueled by a series of positive analyst actions. The biotechnology company has caught the attention of Wall Street, with multiple firms expressing optimism about its future prospects.

Leading the charge, Wells Fargo has significantly raised its price target for Bicara Therapeutics to $11 from $8, indicating a renewed confidence in the company's potential. This upgrade was followed by reaffirmations from other prominent analysts. H.C. Wainwright's analyst Robert Burns reiterated a Buy rating on BCAX with an ambitious price target of $40, while Stifel Nicolaus analyst Stephen Willey maintained a Buy rating with an even more bullish price target of $48.

These positive assessments from Wall Street analysts appear to be the primary driver behind today's stock surge. Investors are responding favorably to the increased price targets and maintained Buy ratings, which suggest strong growth potential for Bicara Therapeutics. As the company continues to develop its pipeline of innovative therapeutics, market participants seem to be betting on its long-term success in the competitive biotechnology sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1152698193"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152698193\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152698193?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 23:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152698193","market":"us","top_or_hot":-1,"title":"Stock Track | Bicara Therapeutics Soars 5% as Multiple Analysts Boost Price Targets","media":"Stock Track","content":"<p>Shares of Bicara Therapeutics (BCAX) are soaring 5.03% in Tuesday's trading session, fueled by a series of positive analyst actions. The biotechnology company has caught the attention of Wall Street, with multiple firms expressing optimism about its future prospects.</p>\n\n<p>Leading the charge, Wells Fargo has significantly raised its price target for Bicara Therapeutics to $11 from $8, indicating a renewed confidence in the company's potential. This upgrade was followed by reaffirmations from other prominent analysts. H.C. Wainwright's analyst Robert Burns reiterated a Buy rating on BCAX with an ambitious price target of $40, while Stifel Nicolaus analyst Stephen Willey maintained a Buy rating with an even more bullish price target of $48.</p>\n\n<p>These positive assessments from Wall Street analysts appear to be the primary driver behind today's stock surge. Investors are responding favorably to the increased price targets and maintained Buy ratings, which suggest strong growth potential for Bicara Therapeutics. As the company continues to develop its pipeline of innovative therapeutics, market participants seem to be betting on its long-term success in the competitive biotechnology sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bicara Therapeutics Soars 5% as Multiple Analysts Boost Price Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bicara Therapeutics Soars 5% as Multiple Analysts Boost Price Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-11 23:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Bicara Therapeutics (BCAX) are soaring 5.03% in Tuesday's trading session, fueled by a series of positive analyst actions. The biotechnology company has caught the attention of Wall Street, with multiple firms expressing optimism about its future prospects.</p>\n\n<p>Leading the charge, Wells Fargo has significantly raised its price target for Bicara Therapeutics to $11 from $8, indicating a renewed confidence in the company's potential. This upgrade was followed by reaffirmations from other prominent analysts. H.C. Wainwright's analyst Robert Burns reiterated a Buy rating on BCAX with an ambitious price target of $40, while Stifel Nicolaus analyst Stephen Willey maintained a Buy rating with an even more bullish price target of $48.</p>\n\n<p>These positive assessments from Wall Street analysts appear to be the primary driver behind today's stock surge. Investors are responding favorably to the increased price targets and maintained Buy ratings, which suggest strong growth potential for Bicara Therapeutics. As the company continues to develop its pipeline of innovative therapeutics, market participants seem to be betting on its long-term success in the competitive biotechnology sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCAX","symbol_name":"Bicara Therapeutics","start_time":0,"source_url":"","article_id":"1152698193","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152698193","pubTimestamp":1762874657,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Bicara Therapeutics (BCAX) are soaring 5.03% in Tuesday's trading session, fueled by a series of positive analyst actions. The biotechnology company has caught the attention of Wall Street,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCAX":"Bicara Therapeutics"},"translate_title":"个股追踪|多位分析师上调目标价，Bicara Therapeutics股价飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCAX":1},"content_text":"Shares of Bicara Therapeutics (BCAX) are soaring 5.03% in Tuesday's trading session, fueled by a series of positive analyst actions. The biotechnology company has caught the attention of Wall Street, with multiple firms expressing optimism about its future prospects.\nLeading the charge, Wells Fargo has significantly raised its price target for Bicara Therapeutics to $11 from $8, indicating a renewed confidence in the company's potential. This upgrade was followed by reaffirmations from other prominent analysts. H.C. Wainwright's analyst Robert Burns reiterated a Buy rating on BCAX with an ambitious price target of $40, while Stifel Nicolaus analyst Stephen Willey maintained a Buy rating with an even more bullish price target of $48.\nThese positive assessments from Wall Street analysts appear to be the primary driver behind today's stock surge. Investors are responding favorably to the increased price targets and maintained Buy ratings, which suggest strong growth potential for Bicara Therapeutics. As the company continues to develop its pipeline of innovative therapeutics, market participants seem to be betting on its long-term success in the competitive biotechnology sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}